By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
Business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases398K100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
United States398K100.00%